HRP20020263A2 - A hepatitis c antigen-antibody combination assay for the early detection of infection - Google Patents
A hepatitis c antigen-antibody combination assay for the early detection of infection Download PDFInfo
- Publication number
- HRP20020263A2 HRP20020263A2 HR20020263A HRP20020263A HRP20020263A2 HR P20020263 A2 HRP20020263 A2 HR P20020263A2 HR 20020263 A HR20020263 A HR 20020263A HR P20020263 A HRP20020263 A HR P20020263A HR P20020263 A2 HRP20020263 A2 HR P20020263A2
- Authority
- HR
- Croatia
- Prior art keywords
- hcv
- antigen
- core
- antibodies
- infection
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title claims description 13
- 208000015181 infectious disease Diseases 0.000 title claims description 6
- 238000003556 assay Methods 0.000 title description 4
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 4
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 description 26
- 239000003599 detergent Substances 0.000 description 11
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 101710132601 Capsid protein Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102200076914 rs104893959 Human genes 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27927601P | 2001-03-28 | 2001-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20020263A2 true HRP20020263A2 (en) | 2002-12-31 |
Family
ID=23068300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020263A HRP20020263A2 (en) | 2001-03-28 | 2002-03-27 | A hepatitis c antigen-antibody combination assay for the early detection of infection |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6723502B2 (enExample) |
| EP (1) | EP1251353A3 (enExample) |
| JP (1) | JP2002365301A (enExample) |
| KR (1) | KR100844169B1 (enExample) |
| CN (1) | CN1378085A (enExample) |
| AR (1) | AR033448A1 (enExample) |
| AU (1) | AU785380B2 (enExample) |
| BR (1) | BRPI0200986B8 (enExample) |
| CZ (1) | CZ305181B6 (enExample) |
| HR (1) | HRP20020263A2 (enExample) |
| HU (1) | HU227950B1 (enExample) |
| MX (1) | MXPA02003318A (enExample) |
| PL (1) | PL353045A1 (enExample) |
| SG (1) | SG118120A1 (enExample) |
| ZA (1) | ZA200202477B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101683B2 (en) * | 2001-06-26 | 2006-09-05 | Abbott Laboratories | Methods for the simultaneous detection of HCV antigens and HCV antibodies |
| US20030108563A1 (en) * | 2001-11-07 | 2003-06-12 | Chander Bahl | Reagents for the simultaneous detection of HCV core antigens and antibodies |
| US7332269B2 (en) * | 2001-11-11 | 2008-02-19 | Ortho-Clinical Diagnostics, Inc. | HCV core protein sequences |
| US7764416B2 (en) | 2006-12-04 | 2010-07-27 | 3M Innovative Properties Company | Electrochromic device based on layer by layer deposition |
| CN101196518B (zh) * | 2006-12-07 | 2011-11-02 | 北京科美东雅生物技术有限公司 | 丙型肝炎病毒抗体化学发光法诊断试剂盒及其制备方法 |
| RU2380711C2 (ru) * | 2008-04-22 | 2010-01-27 | Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Способ изготовления рабочего стандарта сывороток, содержащих антитела к вирусу гепатита с |
| ES2497016T3 (es) * | 2009-03-30 | 2014-09-22 | bioMérieux | Soporte sólido de detección del VHC |
| US20100297607A1 (en) * | 2009-05-20 | 2010-11-25 | Jian Zheng | Reagents For HCV Antigen-Antibody Combination Assays |
| FR2984328B1 (fr) | 2011-12-20 | 2016-12-30 | Bio-Rad Innovations | Procede de detection d'une infection par le virus de l'hepatite c |
| CN102955028A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体抗ama-m2型抗体的试剂盒及其检测方法 |
| CN103630690B (zh) * | 2013-12-17 | 2014-08-20 | 朱之炜 | 丙型肝炎病毒抗原抗体联合检测试剂盒及其检测方法 |
| CN104849460A (zh) * | 2015-05-29 | 2015-08-19 | 山东博科生物产业有限公司 | 一种稳定的丙型肝炎病毒核心抗原酶结合物稀释液 |
| JP2020501601A (ja) | 2016-11-15 | 2020-01-23 | クエスト ダイアグノスティックス インヴェストメンツ エルエルシー | Ｍｉｔｒａチップ抽出を使用して嚢胞性線維症の変異を検出するための方法 |
| WO2021134302A1 (zh) * | 2019-12-30 | 2021-07-08 | 深圳迈瑞生物医疗电子股份有限公司 | 用于检测hcv的免疫分析仪、方法及试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616460A (en) * | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Buffer composition for reagents for immunoassay |
| CA2305192C (en) * | 1998-07-30 | 2009-10-13 | Advanced Life Science Institute, Inc. | Method for assaying hepatitis c virus |
| US6623921B2 (en) * | 1998-07-30 | 2003-09-23 | Advanced Life Science Institute, Inc. | Method for measurement of hepatitis C virus |
| CN100463922C (zh) * | 2000-06-15 | 2009-02-25 | 诺华疫苗和诊断公司 | 抗hcv抗体的免疫测定 |
-
2002
- 2002-03-25 AR ARP020101089A patent/AR033448A1/es not_active Application Discontinuation
- 2002-03-25 SG SG200201677A patent/SG118120A1/en unknown
- 2002-03-25 AU AU27641/02A patent/AU785380B2/en not_active Ceased
- 2002-03-27 MX MXPA02003318A patent/MXPA02003318A/es active IP Right Grant
- 2002-03-27 ZA ZA200202477A patent/ZA200202477B/xx unknown
- 2002-03-27 PL PL02353045A patent/PL353045A1/xx not_active Application Discontinuation
- 2002-03-27 EP EP02252195A patent/EP1251353A3/en not_active Withdrawn
- 2002-03-27 HR HR20020263A patent/HRP20020263A2/hr not_active Application Discontinuation
- 2002-03-27 BR BRPI0200986A patent/BRPI0200986B8/pt not_active IP Right Cessation
- 2002-03-27 CZ CZ2002-1084A patent/CZ305181B6/cs not_active IP Right Cessation
- 2002-03-27 KR KR1020020016640A patent/KR100844169B1/ko not_active Expired - Fee Related
- 2002-03-28 US US10/108,610 patent/US6723502B2/en not_active Expired - Lifetime
- 2002-03-28 JP JP2002092218A patent/JP2002365301A/ja active Pending
- 2002-03-28 HU HU0201087A patent/HU227950B1/hu not_active IP Right Cessation
- 2002-03-28 CN CN02119215A patent/CN1378085A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR100844169B1 (ko) | 2008-07-04 |
| BR0200986A (pt) | 2003-06-10 |
| HUP0201087A2 (hu) | 2003-01-28 |
| CZ20021084A3 (cs) | 2002-11-13 |
| AU2764102A (en) | 2002-10-03 |
| HU227950B1 (hu) | 2012-07-30 |
| HUP0201087A3 (en) | 2004-11-29 |
| BRPI0200986B1 (pt) | 2018-03-20 |
| HU0201087D0 (enExample) | 2002-05-29 |
| US20030049608A1 (en) | 2003-03-13 |
| AU785380B2 (en) | 2007-03-15 |
| PL353045A1 (en) | 2002-10-07 |
| EP1251353A3 (en) | 2002-10-30 |
| JP2002365301A (ja) | 2002-12-18 |
| AR033448A1 (es) | 2003-12-17 |
| ZA200202477B (en) | 2003-09-29 |
| CZ305181B6 (cs) | 2015-06-03 |
| CN1378085A (zh) | 2002-11-06 |
| EP1251353A2 (en) | 2002-10-23 |
| KR20020077125A (ko) | 2002-10-11 |
| US6723502B2 (en) | 2004-04-20 |
| BRPI0200986B8 (pt) | 2021-07-27 |
| MXPA02003318A (es) | 2004-07-16 |
| SG118120A1 (en) | 2006-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5802595B2 (ja) | 組み合わせｃ型肝炎ウイルス抗原及び抗体検出法 | |
| HRP20020263A2 (en) | A hepatitis c antigen-antibody combination assay for the early detection of infection | |
| KR101828767B1 (ko) | Ｈｃｖ 항원-항체 조합 분석용 시약 | |
| PL213363B1 (pl) | Stale podloze immunotestu, sposób wykrywania zakazenia wirusem zapalenia watroby typu C (HCV), zestaw immunodiagnostyczny i sposób wytwarzania stalego podloza immunotestu | |
| CZ315094A3 (en) | Immunoassay | |
| JP2022500677A (ja) | ジカウイルスイムノアッセイの方法および試薬 | |
| Zhu et al. | Development of peptide-based chemiluminescence enzyme immunoassay (CLEIA) for diagnosis of dengue virus infection in human | |
| CA2303123C (en) | Method for detecting antibodies in a sample | |
| CN112341527B (zh) | Hcv重组抗原及应用 | |
| JP2003202345A (ja) | Ｈｃｖコア抗原及び抗体の同時検出試薬 | |
| KR20210011273A (ko) | 지카 바이러스 외피 단백질 도메인 ⅲ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 | |
| JP2008261841A (ja) | Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法 | |
| Ali et al. | Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays | |
| KR102227257B1 (ko) | 플라비바이러스 외피 단백질 도메인 ⅲ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 | |
| TWI428598B (zh) | 黃病毒科病毒感染之檢測方法 | |
| AU2007200598A1 (en) | A hepatitis C antigen - antibody combination assay for the early detection of HCV infection | |
| RU2084527C1 (ru) | Набор для определения антител к вирусу гепатита c человека (варианты) | |
| SUZUKI et al. | Low temperature dependent IgG3 subclass antibody with low avidity to C100-3 antigen derived from hepatitis C virus in voluntary blood donors | |
| Han et al. | The development of ELISA Kit detecting Chikungunya Virus used a synthetic polypeptide chain | |
| Goh et al. | Ming Guan, Hsiao Ying Chen, Shen Yun Foo, Yee-Joo Tan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080325 Year of fee payment: 7 |
|
| OBST | Application withdrawn |